Biotech Values

[mcbio]

Inasmuch as the phase-2 flu data looked good on both safety and efficacy, the lack of external interest in the program is an enigma.

Yes. Perhaps it's a combo of cost and the threat of an ultimate universal flu vaccine or at least a much better flu vaccine (though the former at least appears to be a ways off).

You meant, norovirus, which VXRT refers to as the lead program.

Oops, yes of course. That's what I get for posting when tired. Given lack of buzz in this CC to me, I think I'm just going to keep VXRT on my radar for a while and don't have plans for any imminent position despite what seems like a pretty cheap valuation to me.